A tighter archive for life-science signals.
Search once, then narrow by source or topic.
UCB boards T cell engager train in $60M upfront deal with Antengene
UCB boards T cell engager train in $60M upfront deal with Antengene
Gilead to acquire cell therapy partner Arcellx for $7.8B
Gilead to acquire cell therapy partner Arcellx for $7.8B
J&J pours $1B into new cell therapy site in Pennsylvania
J&J pours $1B into new cell therapy site in Pennsylvania
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
Catalent plans to close Belgium cell therapy site
Catalent plans to close Belgium cell therapy site
Bristol Myers signs deal with Janux on T cell engager for $50M upfront
Bristol Myers signs deal with Janux on T cell engager for $50M upfront
ImmunityBio's cell therapy posts encouraging early data in rare blood cancer
ImmunityBio's cell therapy posts encouraging early data in rare blood cancer
FDA shares eased manufacturing rules for cell and gene therapies
FDA shares eased manufacturing rules for cell and gene therapies
FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus
FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus
Orca adds $250M in financing to back launch of T cell therapy
Orca adds $250M in financing to back launch of T cell therapy
Medipost gets $140M to take Korean stem cell therapy into US
Medipost gets $140M to take Korean stem cell therapy into US
AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug
AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug
Labcorp backs Cellens in developing physics test aimed at bladder cancer
Ex­clu­sive: Cel­lens rais­es .5M to ad­vance physics-based test for blad­der can­cer Boston-based com­pa­ny Cel­lens se­cur...
J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell
J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell
Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront
Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront
J&J-backed Cellular Origins raises $40M for cell therapy manufacturing
J&J-backed Cellular Origins raises $40M for cell therapy manufacturing
FDA's Pazdur is said to raise questions about commissioners actions, new voucher
That didn't take long. Less than two weeks since appointing Richard Pazdur to lead the FDA's drug center, Commissioner Marty Makary is already finding himself in disagr...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page